The Danish startup-company, Fluoguide, has developed a high-tech product, which makes cancer cells glow. Thus, it becomes easier for the doctors to see if all the cancer cells are removed during the operation.
waiting, however, still extensive and expensive clinical studies before the technique can be used on patients. Therefore, it is just a year old company in the course of the spring on the stock exchange in Sweden in order to scrape the 20 million dollars together.
It tells the company's adm. director, Morten Albrechtsen, to the medium and the MedWatch.
According to the MedWatch bind the specific substance, - as Fluoguide has developed - to the cancer cells. Therefore the cells, fluorescent – with a neongrøn color when exposed to kirurgernes laser equipment during the operation.
For the patient, it has the advantage that the surgeon will get easier to assess whether all cancer cells have come up with.
The luminescent substance works in about half an hour.
Among the founders, as well as in the executive board and the board of directors, according to MedWatch, a strip of heavy names from the world of research as well as biotech and medical.
One of the founders is professor and chief physician Andreas Kjær, from copenhagen university hospital. He is also the research director of the Fluoguide.
According to the MedWatch he explained earlier in the week during an investor, how the luminescent substance ’makes surgeons better at it, the surgeons in advance to do.’
Andreas Kjær expect bl.a., the new technology will make it easier to use robots for complex cancer operations. Photo: Sciencenews.dk
Above all, you can remove it, that lights up, and then check again, if there are still small corners that are luminous, and so would remove them, explained Andreas Kjær.
Known to be left today of cancer cells by between 15 and 60 percent of the operations. It depends, however, on kræfttypen - and where the cancer is. Typically, the remaining cancer cells are treated with chemo - and radiotherapy.
the Aim of the new luminescent substance is thus more effective kræftoperationer, when removed tumors in patients with dangerous diseases such as cancer in the pancreas or the brain.
Potentially the luminescent cancer cells make it possible to automate parts of the operations with robots, which can control for a ’traffic light’.
If successful Fluoguide to achieve a market value of 20 million dollars at the ipo, so expect the company to begin the so-called ’phase 1-studies already for next year.
Phase 1-studies include, according to the Cancer society, a very small group of patients who today have no other treatment.